COVID-19 AND MULTIPLE SCLEROSIS
In this paper, the authors report a patient treated with natalizumab for relapsing-remitting MS who developed COVID-19 and recovered in a few days without complications. After recovery, natalizumab was administered with extended interval dosing, without any reports of worsening or new symptoms. The authors concluded that this case supports avoidance of discontinuing or delaying retreatment over 8 weeks in patients with MS treated with natalizumab who have recovered from a recent COVID-19 infection.
by Marialuisa Zedde and Francesco Cavallieri